LevyRITroendleAJFattuJM. A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin. Circulation1993; 87 (suppl III): III45–53.
2.
DavidsonMH. Fluvastatin long-term extension trial (FLUENT): Summary of efficacy and safety. Presented at the 62nd Congress of the European Atherosclerosis Society, Jerusalem, Israel, September 5–9, 1993.
3.
BradfordRHShearCLChremosANDujouneCDowntonMFranklinFF, Expanded clinical evaluation of lovastatin (EXCEL) study results. III. Efficacy in modifying lipoproteins and implications for managing patients with moderate hypercholesterolemia. Am J Med1991; 91 (suppl 1B): 18S–24S.
4.
JokubaitisLATroendleAGFattuJMLevyRI. Clinical experience with fluvastatin, the first synthetic HMG-CoA reductase inhibitor. In: CatapanoAL, ed. Drugs affecting lipid metabolism. The Netherlands: Kluwer Academic Publishers and Fondazione Giovanni Lorenzini, 1993: 269–76.
5.
SmithHTJokubaitisLATroendleAJHwangDSRobinsonWT. Pharmacokinetics of fluvastatin and specific drug interactions. Am J Hypertens1993; 6: 375S–82S.
6.
GarnettWRVenitzJWilkensRCDimennaG. Pharmacokinetic effects of fluvastatin in patients chronically receiving digoxin. Am J Med (in press).
